



Valiant Organics Limited

June 06, 2023

To,
Listing/Compliance Department
BSE LTD.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001.

Scrip Code-540145

To,
Listing/Compliance Department
**National Stock Exchange of
India Limited**
“Exchange Plaza “Plot No .C/1,
G Block Bandra –Kurla Complex,
Bandra (E), Mumbai -400051.
Symbol- VALIANTORG

Subject: Proposed Initial Public Offering of Valiant Laboratories Limited
Ref: Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and further to our intimation dated January 31, 2023 on the subject, we wish to inform you that the Company's material subsidiary namely, Valiant Laboratories Limited (“**VLL**”) has filed a draft red herring prospectus dated June 05, 2023 with the Securities and Exchange Board of India (“**SEBI**”) in relation to its proposed Initial Public Offering (“**the IPO**”) by way of fresh issue of up to 11,556,000 Equity Shares (“**the Issue**”) for listing on BSE Limited (“**BSE**”) and National Stock Exchange of India Limited (“**NSE**”).

VLL is an Active Pharmaceutical Ingredient / Bulk Drug (“**API**”) manufacturing Company having focus on manufacturing of Paracetamol.

The proposed listing and Issue price of Equity Shares are subject to many factors including but not limited to regulatory approvals, book building process under Indian regulations, external factors and prevailing market conditions. Shareholders and potential Investors are advised to exercise caution before taking an investment decision in the Issue.

Kindly take the same on your record.

Thanking you.

Yours faithfully,
For **Valiant Organics Limited**

Avani D. Lakhani
Company Secretary
ICSI M.NO.: A47118